Events & Presentations

Document	Type
Sep 07, 2023	Corporate Presentation 3.4 MB

More events are coming soon.

Date	Event Details
Sep 11, 2023 2:30 PM EDT	H.C. Wainwright 25th Annual Global Investment Conference Listen to webcast
Sep 6, 2023 10:30 AM EDT	Citi’s 2023 18th Annual BioPharma Conference Listen to webcast
Aug 9, 2023 4:30 PM EDT	MacroGenics, Inc. Second Quarter 2023 Financial Results Conference Call Listen to webcast
May 9, 2023 4:30 PM EDT	MacroGenics, Inc. First Quarter 2023 Financial Results Conference Call Listen to webcast
Mar 15, 2023 4:30 PM EDT	MacroGenics, Inc. Fourth Quarter 2022 Financial Results Conference Call Listen to webcast
Feb 16 - Feb 18, 2023	ASCO-Genitourinary Cancers Symposium 2023 Conference Feb 16-18 Supporting Materials Lorigerlimab (PD-1 × CTLA-4) Phase 1 Study Expansion Data in Patients with mCRPC 847.6 KB
Nov 3, 2022 4:30 PM EDT	MacroGenics, Inc. Third Quarter 2022 Financial Results Conference Call Listen to webcast
Aug 8, 2022 4:30 PM EDT	MacroGenics, Inc. Second Quarter 2022 Financial Results Conference Call Listen to webcast
Jun 3 - Jun 7, 2022	ASCO 2022 Annual Meeting Supporting Materials Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives 1 MB
May 3, 2022 4:30 PM EDT	MacroGenics, Inc. First Quarter 2022 Financial Results Conference Call Listen to webcast
Apr 8 - Apr 13, 2022	American Association for Cancer Research (AACR) Annual Meeting poster presentations Supporting Materials Targeting B7-H3 in Prostate Cancer: Preclinical Proof-of-Concept with MGC018, an Investigational Anti-B7-H3 Antibody-drug Conjugate 9.9 MB
Feb 24, 2022 4:30 PM EST	MacroGenics, Inc. Fourth Quarter 2021 Financial Results Conference Call Listen to webcast
Dec 11 - Dec 13, 2021	63rd ASH Annual Meeting & Exposition Supporting Materials Combinatorial Anti-Tumor Activity in Animal Models of a Novel CD123 x CD3 Bispecific DART® Molecule (MGD024) with Cytarabine, Venetoclax or Azacitidine Supports Combination Therapy in Acute Myeloid Leukemia 1.8 MB
Dec 7 - Dec 10, 2021	2021 San Antonio Breast Cancer Symposium (SABCS) Supporting Materials Phase 3 SOPHIA Study of Margetuximab + Chemotherapy Versus Trastuzumab + Chemotherapy in Patients With HER2+ Metastatic Breast Cancer After Prior Anti-HER2 Therapies: Final Overall Survival Analysis 583.6 KB
Nov 2, 2021 4:30 PM EDT	MacroGenics, Inc. Third Quarter 2021 Financial Results Conference Call Listen to webcast
Sep 16, 2021 2:45 AM EDT	ESMO 2021 Virtual Annual Congress Supporting Materials MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors: Preliminary Results of Phase 1 Cohort Expansion 814.4 KB Margetuximab With Retifanlimab in HER2+, PD-L1+ First-Line Unresectable/Metastatic Gastroesophageal Adenocarcinoma (GEA): MAHOGANY Cohort A 3 MB Phase 2 Trial of Enoblituzumab Plus Retifanlimab or Tebotelimab in First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (TiP) 594.5 KB
Jul 29, 2021 4:30 PM EDT	MacroGenics, Inc. Second Quarter 2021 Financial Results Conference Call Listen to webcast
Jun 4 - Jun 8, 2021	ASCO 2021 Annual Meeting Supporting Materials Phase 1 Dose Escalation Study of MGC018, an anti-B7-H3 ADC In Patients with Advanced Solid Tumors 549.4 KB
Jun 4, 2021 4:30 PM EDT	MacroGenics – MGC018 ASCO Conference Call Listen to webcast Supporting Materials View Presentation 4.4 MB
Apr 29, 2021 4:30 PM EDT	MacroGenics, Inc. First Quarter 2021 Financial Results Conference Call Listen to webcast
Apr 10 - Apr 15, 2021	American Association for Cancer Research (AACR) Annual Meeting poster presentations: Supporting Materials Enhanced HER2-dependent immune activation by margetuximab supports combination with checkpoint blockade 991.2 KB Targeting B7-H3 in SCCHN: Preclinical proof-of-concept with MGC018, investigational anti-B7-H3 ADC 4.8 MB IMGC936 (investigational ADAM9-targeting ADC) is active against patient-derived ADAM9-expressing xenograft models 555.9 KB
Feb 25, 2021 4:30 PM EST	MacroGenics, Inc. Fourth Quarter 2020 Financial Results Conference Call Listen to webcast
Dec 17, 2020 8:00 AM EST	MARGENZA™ Approval Conference Call Listen to webcast Supporting Materials View Presentation 1 MB
Dec 5 - Dec 8, 2020	62nd ASH Annual Meeting & Exposition Supporting Materials Microenvironmental Immune Senescence and Exhaustion in AML Associate w Response to Flotetuzumab 2.9 MB TP53 Abnormalities - Response to Flotetuzumab in AML (Rutella) 1 MB Flotetuzumab (CD123 x CD3) as Salvage Therapy for PIF and ER AML (Aldoss) 976.1 KB Flotetuzumab Upregulates MHC Class II Expression on AML (Rimando) 696.9 KB Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in AML (Rutella) 22.4 MB Phase 1 Study of MGD013 (Tebotelimab, PD-1 x LAG-3) in Patients with RR DLBCL (Wang) 912.2 KB Prophylactic Ruxolitinib for CRS in RR AML Pts Treated w Flotetuzumab (Uy) 653 KB